OBJECTIVE: To review the current state of the art regarding the role of the clinical laboratory in diagnostic testing for the factor V Leiden (FVL) thrombophilic mutation (and other protein C resistance disorders), and to generate, through literature reviews and opinions of recognized thought-leaders, expert consensus recommendations on methodology and diagnostic, prognostic, and management issues pertaining to clinical FVL testing. DATA SOURCES, EXTRACTION, AND SYNTHESIS: An initial thorough review of the medical literature and of current best clinical practices by a panel of 4 experts followed by a consensus conference review, editing, and ultimate approval by the majority of a panel of 28 additional coagulation laboratory experts. CONCLUSIONS: Consensus recommendations were generated for topics of direct clinical relevance, including (1) defining those patients (and family members) who should (and should not) be tested for FVL; (2) defining the preferred FVL laboratory testing methods; and (3) defining the therapeutic, prophylactic, and management ramifications of FVL testing in affected individuals and their family members. As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation.
OBJECTIVE: To review the current state of the art regarding the role of the clinical laboratory in diagnostic testing for the factor V Leiden (FVL) thrombophilic mutation (and other protein C resistance disorders), and to generate, through literature reviews and opinions of recognized thought-leaders, expert consensus recommendations on methodology and diagnostic, prognostic, and management issues pertaining to clinical FVL testing. DATA SOURCES, EXTRACTION, AND SYNTHESIS: An initial thorough review of the medical literature and of current best clinical practices by a panel of 4 experts followed by a consensus conference review, editing, and ultimate approval by the majority of a panel of 28 additional coagulation laboratory experts. CONCLUSIONS: Consensus recommendations were generated for topics of direct clinical relevance, including (1) defining those patients (and family members) who should (and should not) be tested for FVL; (2) defining the preferred FVL laboratory testing methods; and (3) defining the therapeutic, prophylactic, and management ramifications of FVL testing in affected individuals and their family members. As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation.
Authors: K A B Goddard; J Robitaille; N F Dowling; A R Parrado; J Fishman; L A Bradley; C A Moore; M J Khoury Journal: Public Health Genomics Date: 2008-11-26 Impact factor: 2.000
Authors: Ahmet Karatas; Recep Eroz; Mustafa Albayrak; Tulay Ozlu; Bulent Cakmak; Fatih Keskin Journal: Afr Health Sci Date: 2014-03 Impact factor: 0.927
Authors: Cannon Milani; Maria Constantinou; David Berz; James N Butera; Gerald A Colvin Journal: J Hematol Oncol Date: 2008-12-02 Impact factor: 17.388
Authors: Lucia A Hindorff; Wylie Burke; Anne-Marie Laberge; Kenneth M Rice; Thomas Lumley; Kathleen Leppig; Frits R Rosendaal; Eric B Larson; Bruce M Psaty Journal: Arch Intern Med Date: 2009-01-12